Clinical trials: Advanced Rectal Cancers
Colorectal Cancer (CRC), Tumor Infiltrating Lymphocytes
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer
TIL from tumor tissue of advanced colorectal cancer patients were cultured, modified and expanded in vitro, and then transfused back to the patients after quality control.
- Conditions
- Colorectal Cancer (CRC), Tumor Infiltrating Lymphocytes, PD-1
- Trial name
- NCT07035002
- Testing
- transfusion of 5×10^8 PD-1 knockout TILs per kg body weight, transfusion of 1×10^9 PD-1 edited TILs per kg body weight, transfusion of 2×10^9 PD-1 edited TILs per kg body weight
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Ruijin Hospital
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer
This phase I trial studies the best dose and side effects of irinotecan hydrochloride when given with utomilumab and cetuximab in treating patients with colorectal cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8
- Trial name
- NCT03290937
- Testing
- Cetuximab, Irinotecan Hydrochloride, Pharmacodynamic Study
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Anal Squamous Cell Carcinoma
Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer
The goal of this clinical trial is to see the safety and efficacy of pembrolizumab and lenvatinib in patients with anal squamous cell cancer that cannot be removed through surgery or is spread to other organs.
- Trial name
- NCT07680088
- Testing
- Lenvatinib, Pembrolizumab
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Colorectal Cancer, Adenoma
Effect of an Advanced Notification Letter on Screening Colonoscopy Participation
Participation in a primary screening colonoscopy programs remains low. Advanced notification letter has been shown to increase participation in colorectal cancer screening with fecal occult blood testing and to be cost effective…
- Conditions
- Colorectal Cancer, Adenoma, Rectal Cancer
- Trial name
- NCT02188927
- Testing
- Implementation of ANL, No included ANL
- Where
- Poland
- Volunteers
- 6,800 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
This phase I trial studies the side effects and best dose of ropidoxuridine in treating patients with gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment…
- Conditions
- Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT02381561
- Testing
- Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Trial of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer
Pathological complete response, (pCR) correlates with a favorable overall prognosis in locally advanced rectal cancer patients underwent preoperative chemoradiation, so obtaining a pCR might be beneficial.
- Trial name
- NCT02195141
- Testing
- conventional fraction, SIB
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Chinese Academy of Medical Sciences
Colon Cancer, Rectum Cancer
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
Research Hypothesis: Subjects in the study population who are treated with cetuximab in combination with irinotecan will have higher response rates than subjects treated with irinotecan alone.
- Trial name
- NCT00336856
- Testing
- Cetuximab, Irinotecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Pittsburgh
Mid-low Rectal Cancer
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer
- Trial name
- NCT06333769
- Testing
- Short-course Radiotherapy, Tislelizumab, Capecitabine
- Where
- 3 sites in China
- Volunteers
- 38 people
- Sponsor
- Fujian Cancer Hospital
Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Molecular Study and Precision Medicine for Colorectal Cancer
Researchers collect specimens from advanced or recurrent colorectal cancer (CRC) patients to conduct molecular profiling and establish tumor organoids (PDOs)/ patient-derived xenografts (PDXs).
- Trial name
- MSPM (NCT05883683)
- Testing
- Molecular Profiling & drug testing in tumor organoids and PDXs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced or Metastatic Solid Tumors
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are…
- Trial name
- NCT06781983
- Testing
- IPH4502
- Where
- 7 sites in United States, France
- Volunteers
- 145 people
- Sponsor
- Innate Pharma
Locally Advanced Rectal Carcinoma
Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer
The goal of this clinical trial is to investigate total neoadjuvant therapy (TNT) using short course radiation therapy (SCRT) followed by full course of chemotherapy then surgery in locally advanced rectal cancer.
- Trial name
- NCT05622357
- Testing
- short course radiation therapy followed by 6 cycles of CAPOX then surgery
- Where
- Egypt
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute, Egypt
Metastatic Colorectal Cancer
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
This will be a multicenter, open-label study enrolling a total of up to 23 patients.
- Trial name
- NCT00851136
- Testing
- bevacizumab, FOLFOX, PRO95780
- Volunteers
- 9 people
- Sponsor
- Genentech, Inc.
Breast Cancer, Non-small Cell Lung Cancer
Integrated Molecular Profiling in Advanced Cancers Trial
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer
- Trial name
- IMPACT (NCT01505400)
- Where
- Canada
- Volunteers
- 3,026 people
- Sponsor
- University Health Network, Toronto
Colorectal Neoplasms
Dendritic Cell Vaccination in Patients With Advanced Colorectal Cancer
Dendritic cells loaded with tumor antigens induce cytotoxic T-cells which have been proved capable of killing both melanoma and breast cancer cells. Melanoma and colorectal cancer cells express some common antigens.
- Trial name
- NCT00311272
- Testing
- MelCancerVac
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.
- Trial name
- NCT07446465
- Testing
- Serplulimab, Fruquintinib, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Ye Xu
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Non-small Cell Lung Cancer, Head and Neck Cancer
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03565003
- Testing
- JAB-3068
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Colorectal Cancer
Xeloda Vs Monitoring in Advanced Colorectal Cancer Responsive to Chemotherapy
To compare maintenance chemotherapy with Xeloda to control after best response with first line chemotherapy in advanced colorectal cancer. Main endpoint is progression free survival. A total of 300 patients will be included.
- Trial name
- NCT00189683
- Testing
- Monitoring, Xeloda
- Where
- France
- Sponsor
- Association Européenne de Recherche en Oncologie
Non-small Cell Lung Cancer, Pancreatic Cancer
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Study to compare the effects of the investigational new drug (PF-06946860) and a placebo on appetite and to find out how participants with advanced cancer and anorexia feel after receiving repeated subcutaneous (SC-injected under…
- Conditions
- Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT04803305
- Testing
- PF-06946860
- Where
- 33 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.